
Community Care Pathways in Squamous NSCLC
In this segment, the panel discusses strategies for extending specialized support to community clinicians caring for patients with advanced squamous non-small cell lung cancer (NSCLC), particularly when managing complex treatment-related toxicities.
Episodes in this series

In this segment, the panel discusses strategies for extending specialized support to community clinicians caring for patients with advanced squamous non-small cell lung cancer (NSCLC), particularly when managing complex treatment-related toxicities. Dr. Edward Kim describes a newly launched pathway program designed to provide community providers with structured guidance, including treatment protocols, monitoring requirements, vaccination schedules, and other practical management resources. The program initially operates within the institution's network, with plans to expand access to outside providers after the implementation process is established. The panel emphasizes that these pathways need to remain adaptable as treatment recommendations and supportive care requirements change, particularly for newer therapies with evolving toxicity profiles. Dr. Kim also highlights the importance of making updated guidance readily available to nonexpert clinicians, who may rely heavily on these resources when managing patients outside specialized centers. The discussion concludes by emphasizing referral to a multidisciplinary medical oncology setting when community clinicians encounter unfamiliar or complex toxicities requiring additional expertise.
Related to this article










